Review of the role of the sentinel node biopsy in neoadjuvant chemotherapy in women with breast cancer and negative or positive axillary node at diagnosis

2018 ◽  
Vol 37 (1) ◽  
pp. 63-70
Author(s):  
R. Ruano Pérez ◽  
A.C. Rebollo Aguirre ◽  
P. García-Talavera San Miguel ◽  
R. Díaz Expósito ◽  
S. Vidal-Sicart ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Axillary Node ◽  
Positive Axillary Node ◽  
Node Biopsy

The Predictive Value of Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer Patients who Have Undergone Neoadjuvant Chemotherapy

2007 ◽  
Vol 73 (10) ◽  
pp. 977-980 ◽  
Author(s):  
Maki Yamamoto ◽  
Rita S. Mehta ◽  
Choong H. Baick ◽  
Min-Ying Su ◽  
Karen T. Lane ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
False Negative ◽  
False Negative Rate ◽  
Axillary Node ◽  
Node Biopsy

With the increasing usage of neoadjuvant chemotherapy (NAC) in locally advanced breast cancer (LABC), there is the need to investigate the routine axillary node dissections performed in this group of patients. Controversy exists about the utility of sentinel node biopsy (SNB), either before or after NAC. With the addition of trastuzumab in the treatment of Her2/neu-positive LABC patients, the validity of SNB in this subset population needs to be investigated. A retrospective study of 20 patients who underwent NAC for LABC was undertaken. The pathology of the axillary nodes, sentinel nodes, and primary tumor after neoadjuvant chemotherapy were examined. Twenty patients underwent NAC with doxorubicin and cyclophosphamide, followed sequentially by paclitaxel and carboplatin, with or without trastuzumab based on Her2/neu status. Post chemotherapy, 20 patients underwent mastectomy or lumpectomy with SNB with axillary node dissections. The overall accuracy of SNB was 95 per cent with a false-negative rate of 14 per cent (1/7). In Her2/neu-positive patients, overall accuracy was 100 per cent (8/8) and a false-negative rate of zero per cent. Sentinel node biopsy is a viable option in patients who have undergone NAC. Her2/neu-positive patients who had undergone NAC with trastuzumab had comparable accuracy for sentinel node biopsy in predicting axillary node status.

P336 Outcome of sentinel node biopsy after neoadjuvant chemotherapy in CN0 breast cancer

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S142
Author(s):  
K. Tsugawa ◽  
R. Hayami ◽  
T. Uejima ◽  
Y. Kojima ◽  
T. Nishikawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Sentinel Node ◽  
Sentinel Node Biopsy ◽  
Node Biopsy
Sign in / Sign up

Export Citation Format

Share Document